Xiaoguang Xu

发表

Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells.

Yingli Wu, Hua Yan, J. Mi, 2019, Life sciences.

Integrated analysis of gut microbiome and host immune responses in COVID-19

Shengyue Wang, Y. Ling, Yun Tan, 2022, Frontiers of Medicine.

PathogenTrack and Yeskit: tools for identifying intracellular pathogens from single-cell RNA-sequencing datasets as illustrated by application to COVID-19

Yun Tan, Wei Zhang, Z. Fu, 2022, Frontiers of Medicine.

The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022

Xinxin Zhang, Y. Ling, D. Wei, 2022, Cell Discovery.

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ

Yingli Wu, Hua Yan, Xinyi Zeng, 2020, Cancer Biology and Medicine.

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

Hanzhang Xu, Yingli Wu, Hua Yan, 2021, Cell Death & Disease.

Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy

F. Zhan, Yingli Wu, Hua Yan, 2019, Haematologica.

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yixiao Lin, Hongzhou Lu, Saijuan Chen, 2020, Frontiers of Medicine.

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

Feng Liu, Y. Ling, Zhaoqin Zhu, 2023, Frontiers of Medicine.

Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19

X. Bian, Hongzhou Lu, Y. Ling, 2021, Cell Discovery.

Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19

X. Bian, Hongzhou Lu, Saijuan Chen, 2021, Cell discovery.